REPORT
EXCLUSIVE LIFE SCIENCE FEATURE
24
LIFESCIENCELEADER.COM JULY 2014 CMO SUPPLEMENT
The latest industry trends and proprietary data from Nice Insight survey results
The Percentage by Buyer Group Who
Would Consider Outsourcing to CMOs in
Emerging Markets
■ Biotech ■ Emerging Biotech ■ Big Pharma ■ Specialty Pharma ■ Emerging Pharma
of respondents will consider CMOs in
emerging markets for manufacturing projects
85%
91%
86%
80%
79%
■ Biotech ■ Emerging Biotech ■ Big Pharma ■ Specialty Pharma ■ Emerging Pharma
of respondents are already working with CMOs in
emerging markets on manufacturing projects
56%
73%
41%
51%
34%
The Percentage by Buyer Group Who Are
Already Working with CMOs in Emerging
Markets on Biomanufacturing
■ Biotech ■ Emerging Biotech ■ Big Pharma ■ Specialty Pharma ■ Emerging Pharma
of respondents say the quality level is too
risky to offshore manufacturing projects
11%
5%
7%
8%
12%
The Percentage by Buyer Group Who
Believe the Quality Level Is Too Risky to
Offshore Biomanufacturing Projects
39%
52%
22%
25%
18%
The Percentage of Respondents Who Outsource
Mammalian Cell Culture Services to Emerging
Market CMOs by Buyer Group
Biotech
Emerging Biotech
Big Pharma
Specialty Pharma
Emerging Pharma
The Percentage of Respondents Who Outsource
Microbial Manufacturing Services to Emerging
Market CMOs by Buyer Group
36%
55%
30%
34%
24%
Biotech
Emerging Biotech
Big Pharma
Specialty Pharma
Emerging Pharma
The Percentage of Respondents Who Outsource
Vaccine production to Emerging Market CMOs
by Buyer Group
23%
31%
22%
25%
16%
Biotech
Emerging Biotech
Big Pharma
Specialty Pharma
Emerging Pharma
0 7 1 4 _ R e s e a r c h _ R e p o r t s _ O I _ B i o 2 . i n d d 3 0714_Research_Reports_OI_Bio2.indd 3 6 / 2 0 / 2 0 1 4 1 : 2 3 : 2 2 P M 6/20/2014 1:23:22 PM